Yu et al. demonstrated an increased expression of SYK in paclitaxel-resistant ovarian cancer cells and that paclitaxel in combination with the SYK inhibitor R406 increased apoptosis in vitro and impaired tumor growth in vivo [33]. Here, SYK is linked to ovarian carcinoma.